Board of directors
André Ostachkov joined the board of directors in March 2021, bringing 20 years of finance and business experience to support Theravet’ vision and development. He joined the management team of the Innovation Fund in July 2018. Created in February 2015, Innovation Fund invests in innovative startups and companies active in the field of chemistry and life sciences. The fund has a capital of EUR 35 million, financed for more than 50% by major companies in the sector, bringing unique industrial support value to the investment projects. The remaining 50% is held by national and regional investment funds, universities, banks and individuals. To date, the Innovation Fund has already invested in 31 companies. Mr. Ostachkov serves as a director on a number of boards and strategic committees, including DoseVue, Univercells, Graftys, Apaxen, HomeEos (Belgium), Norimat (France) Prior to this, he worked 17 years within BNP Paribas Corporate Finance at various positions in BeLux, France, Russia and Germany where he advised on a number of M&A and equity capital market transactions. Andre is graduated from Louvain School of Management (Belgium) and ESADE (Barcelona, Spain) in 2001.
Chief Executive Officer
Enrico Bastianelli is the founder of TheraVet. Medical Doctor by training and holder of an MBA, Enrico Bastianelli acquired his business experience at McKinsey & Co. After creating several biotech companies, he founded and led Bone Therapeutics (a human bone cell therapy company) for 10 years. During this period, he took up many challenges such as the company's IPO (2015). He has 20 years of experience in biotech and medtech management.
Lotfi Yelles Chaouche
Lotfi Yelles Chaouche is a Partner with Theodorus Investment Funds where he is in charge of the Lifesciences Investments Theodorus is an early stage VC fund active in Belgium and Canada which invests mainly in university spin-offs; its historical partner being thethe Free University of Brussels (ULB) .Lotfi holds a Master in Aerospace Engineering (M.Eng.) And Business Engineering from ISAE-Supaero (France). He was previously an Engagement Manager at McKinsey & Company where he mostly served the Pharmaceuticals and Medical Devices Industry on a broad range of topics, including innovation and M&A strategy.
Jean-Philippe Mathieu is investment manager at INVESTSUD Group. After a PhD in materials science at the University of Liège and a master's degree in management at HEC Liège, he held various positions in the banking sector for more than 10 years. With his scientific background and expertise in Corporate finance, he has joined the venture capital group, Investsud, 5 years ago. Since then, he has accompanied many companies in start-up phase within different sectors : digital, IoT, Medtech...
Julie Winand holds a PhD in Biochemistry and Cellular Biology carried out at the Catholic University of Louvain (Belgium). Before joining TheraVet, Julie worked at Bone Therapeutics and Novasep where she acquired experience in Product and Business Development.